Michael Gilman spent roughly a decade building Arrakis Therapeutics from a seed-stage idea into a company on the verge of its first clinical trial, and the person chosen to take it across that threshold carries a specific credential: Mark DeLong just helped engineer a $5.6 billion acquisition of Apellis Pharmaceuticals by Biogen, closing in May 2026. That is not a typical pre-IND CEO résumé, and it signals something deliberate about where Arrakis sees its near-term leverage.
The strategic logic is tight. Arrakis is advancing an oral small molecule that binds directly to the pathogenic trinucleotide RNA repeat driving myotonic dystrophy type 1, a genetic disease long managed with symptomatic care rather than anything that touches the underlying mutation. The compound is designed to exploit what small molecules do well: systemic biodistribution, oral dosing, and manufacturing scale that biologics and antisense therapies cannot match. DeLong’s background sits at the intersection of business development and late-stage clinical execution, exactly the profile a board installs when the next 18 months require both a clean IND filing and serious partnership conversations. Apellis, under his tenure as Chief Business and Strategy Officer, took two drugs through FDA approval and commercialization, which is operationally the harder part of drug development and the part Arrakis has never done.
The RNA-targeting small molecule space is moving fast enough that timing genuinely matters. Remix Therapeutics is already running two Phase I trials in 2026 with its RNA-splicing modulator REM-422, in oncology indications. Arrakis is working a different mechanism in a rare disease, but the broader category is attracting scrutiny from larger acquirers, and the window to establish clinical proof-of-concept as an independent company is finite. Gilman moving to Chairman rather than departing cleanly suggests the board wants institutional continuity through the IND and early dosing, not a clean break. The governance shuffle, with Katrine Bosley stepping off entirely, concentrates decision-making authority in a tighter circle precisely when clinical execution demands it.
The single marker worth tracking is when Arrakis files its IND for the DM1 candidate. That filing date will clarify whether DeLong’s appointment was a preparation for a partnership deal or a commitment to building clinical data independently before any strategic transaction.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
